The selective P-TEFb inhibitor CAN508 targets angiogenesise

0368596 - ÚEB 2012 RIV FR eng J - Journal Article
Kryštof, Vladimír - Rárová, Lucie - Liebl, J. - Zahler, S. - Jorda, Radek - Voller, Jiří - Cankař, Petr
The selective P-TEFb inhibitor CAN508 targets angiogenesise.
European Journal of Medicinal Chemistry. Roč. 46, č. 9 (2011), s. 4289-4294. ISSN 0223-5234. E-ISSN 1768-3254
R&D Projects: GA ČR GA204/08/0511; GA ČR GA301/08/1649
Institutional research plan: CEZ:AV0Z50380511
Keywords : Angiogenesis * Cancer * Transcription * Inhibitor * Cyclin-dependent kinase 9
Subject RIV: CE - Biochemistry
Impact factor: 3.346, year: 2011

Small molecule inhibitors of cyclin-dependent kinases (CDK) have been developed as anticancer drugs with cytostatic and cytotoxic properties, but some of them have also been shown to limit angiogenesis. Here, we report that the 3,5-diaminopyrazole CAN508 inhibits endothelial cell migration and tube formation. In addition, it reduces phosphorylation of the C-terminus of RNA polymerase II and inhibits mRNA synthesis in endothelial cells, in accordance with previous observations that it has high selectivity towards the positive transcriptional regulator P-TEFb. Moreover, CAN508 reduces expression of vascular endothelial growth factor by several human cancer cell lines. The findings suggest that P-TEFb may be an attractive target for anti-angiogenic therapy. (C) 2011 Elsevier Masson SAS. All rights reserved.
Permanent Link: http://hdl.handle.net/11104/0202895